PROTAC Discovery
Translational Development
Live Cell Imaging
Based upon our decades of expertise of discovery of immunomodulatory drugs (IMiDs), we help:
- Identify and characterize new, potent, and selective ligands that bind and reprogram E3 ligase substrate specificity with our ligand binding assay.
- Develop, characterize, and validate the warhead end of novel PROTACs.
- Enable sensitive quantitation of PROTAC-mediated degradation of targets for DC50 and Dmax values
- Evaluate the impact of target degraders on efficacy and safety-related translational biomarkers with our automatic western blot, IHC and other platforms.
- Characterize PROTAC selectivity across the proteome and provide a global readout on changes in protein expression using protein microarray such as RPPA.
- Provide on-shelf assays, such as CRBN, BET-VHL binding assay, VHL and CRBN ternary complex formation assay